📊 AMPH Key Takeaways
Is Amphastar Pharmaceuticals, Inc. (AMPH) a Good Investment?
Amphastar demonstrates solid operational fundamentals with strong profitability (19.5% operating margin, 13.6% net margin) and excellent cash generation (121.2M free cash flow, 16.8% FCF margin). The company maintains a fortress balance sheet with robust liquidity (4.02x current ratio) and manageable leverage (0.79x debt/equity), though top-line growth challenges and declining EPS require monitoring.
Amphastar Pharmaceuticals shows solid core fundamentals, with healthy profitability, strong free cash flow generation, and very strong liquidity despite a leveraged balance sheet. However, revenue declined slightly year over year, net income was flat, and diluted EPS fell sharply, which points to weaker growth quality and limits conviction until operating momentum improves.
Why Buy Amphastar Pharmaceuticals, Inc. Stock? AMPH Key Strengths
- Exceptional cash flow generation with 121.2M FCF and 16.8% FCF margin demonstrating operational efficiency
- Strong profitability metrics across all margins (49.5% gross, 19.5% operating, 13.6% net) indicating pricing power and cost control
- Fortress balance sheet with 4.02x current ratio, 2.90x quick ratio, and 16.3x interest coverage providing financial flexibility
- Solid ROE of 12.4% and ROA of 6.0% indicating effective capital deployment despite stagnant growth
- Strong liquidity profile with 4.02x current ratio and 2.90x quick ratio
- Solid profitability with 49.5% gross margin, 19.5% operating margin, and 13.6% net margin
- Healthy cash generation with $156.12M operating cash flow and $121.23M free cash flow
AMPH Stock Risks: Amphastar Pharmaceuticals, Inc. Investment Risks
- Revenue decline of 1.7% YoY and flat net income growth suggesting loss of market momentum or competitive pressures
- Diluted EPS contracted 33.7% YoY despite stable net income, indicating share dilution from equity issuances or acquisitions
- High debt load of 619.7M (43.5% of assets) limits financial flexibility despite adequate coverage ratios
- Pharmaceutical sector exposure to regulatory risks, patent expirations, and pricing pressures that could impact future margins
- Revenue contraction of 1.7% suggests limited near-term growth momentum
- Diluted EPS declined 33.7% year over year despite flat net income, indicating weaker per-share earnings quality
- Long-term debt of $619.71M and 0.79x debt-to-equity increase balance sheet risk if earnings soften
Key Metrics to Watch
- Quarterly revenue trends to confirm stabilization or reversal of declining sales
- Operating margin sustainability as pricing pressures and competitive dynamics evolve
- Free cash flow consistency and capital allocation decisions with existing debt levels
- Debt reduction progress relative to operating cash generation capacity
- Revenue growth and operating income trend
- Diluted EPS trend and long-term debt reduction
Amphastar Pharmaceuticals, Inc. (AMPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.02x current ratio provides a solid financial cushion.
AMPH Profit Margin, ROE & Profitability Analysis
AMPH vs Healthcare Sector: How Amphastar Pharmaceuticals, Inc. Compares
How Amphastar Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Amphastar Pharmaceuticals, Inc. Stock Overvalued? AMPH Valuation Analysis 2026
Based on fundamental analysis, Amphastar Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Amphastar Pharmaceuticals, Inc. Balance Sheet: AMPH Debt, Cash & Liquidity
AMPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Amphastar Pharmaceuticals, Inc.'s revenue has grown significantly by 67% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.60 reflects profitable operations.
AMPH Revenue Growth, EPS Growth & YoY Performance
AMPH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $191.2M | $17.4M | $0.37 |
| Q2 2025 | $174.4M | $25.3M | $0.64 |
| Q1 2025 | $170.5M | $25.3M | $0.51 |
| Q3 2024 | $180.6M | $26.0M | $0.78 |
| Q2 2024 | $145.7M | $26.0M | $0.49 |
| Q1 2024 | $140.0M | $26.0M | $0.50 |
| Q3 2023 | $120.1M | $15.9M | $0.30 |
| Q2 2023 | $123.5M | $17.3M | $0.33 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Amphastar Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
AMPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Amphastar Pharmaceuticals, Inc. (CIK: 0001297184)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 13, 2026 | DEF 14A | amph-20260601xdef14a.htm | View → |
| Mar 17, 2026 | 4 | xslF345X05/form4-03182026_120345.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/form4-03172026_100316.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/form4-03172026_100317.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/form4-03172026_100314.xml | View → |
❓ Frequently Asked Questions about AMPH
What is the AI rating for AMPH?
Amphastar Pharmaceuticals, Inc. (AMPH) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (HOLD) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AMPH's key strengths?
Claude: Exceptional cash flow generation with 121.2M FCF and 16.8% FCF margin demonstrating operational efficiency. Strong profitability metrics across all margins (49.5% gross, 19.5% operating, 13.6% net) indicating pricing power and cost control. ChatGPT: Strong liquidity profile with 4.02x current ratio and 2.90x quick ratio. Solid profitability with 49.5% gross margin, 19.5% operating margin, and 13.6% net margin.
What are the risks of investing in AMPH?
Claude: Revenue decline of 1.7% YoY and flat net income growth suggesting loss of market momentum or competitive pressures. Diluted EPS contracted 33.7% YoY despite stable net income, indicating share dilution from equity issuances or acquisitions. ChatGPT: Revenue contraction of 1.7% suggests limited near-term growth momentum. Diluted EPS declined 33.7% year over year despite flat net income, indicating weaker per-share earnings quality.
What is AMPH's revenue and growth?
Amphastar Pharmaceuticals, Inc. reported revenue of $719.9M.
Does AMPH pay dividends?
Amphastar Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find AMPH SEC filings?
Official SEC filings for Amphastar Pharmaceuticals, Inc. (CIK: 0001297184) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AMPH's EPS?
Amphastar Pharmaceuticals, Inc. has a diluted EPS of $2.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AMPH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Amphastar Pharmaceuticals, Inc. has a BUY rating with 76% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is AMPH stock overvalued or undervalued?
Valuation metrics for AMPH: ROE of 12.4% (sector avg: 15%), net margin of 13.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AMPH stock in 2026?
Our dual AI analysis gives Amphastar Pharmaceuticals, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is AMPH's free cash flow?
Amphastar Pharmaceuticals, Inc.'s operating cash flow is $156.1M, with capital expenditures of $34.9M. FCF margin is 16.8%.
How does AMPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 13.6% (avg: 12%), ROE 12.4% (avg: 15%), current ratio 4.02 (avg: 2).